01—Abstract
Summary
Summary of the 8-K filed February 4, 2025. Cited figures are marked; the original filing is the authoritative source.
Amgen reported fourth-quarter and full-year 2024 results that combined strong top-line growth with a sharp GAAP earnings decline.
Q4 total revenues rose 11% to $9.1 billiona and full-year revenues rose 19% to $33.4 billion, driven by volume growth and the Horizon Therapeutics acquisition. Excluding Horizon, full-year product sales grew 7%. Non-GAAP EPS grew 13% in Q4 to $5.31 and 6% for the full year to $19.84, while GAAP EPS fell 39% for the year to $7.56, mainly due to Horizon-related amortization, higher operating expenses, and mark-to-market losses on equity investments, primarily BeiGene.
Cash generation was a clear highlight. Free cash flow reached a record $4.4 billionb in Q4 and $10.4 billion for the full year, up from $7.4 billion in 2023, helped partly by working capital timing. Amgen reduced principal debt by $4.5 billion in 2024, ending the year with $60.1 billion of debt and approximately 4.5x debt leverage on EBITDA.
Management guided 2025 total revenues to $34.3c–35.7 billion and non-GAAP EPS to $20.00–21.20, with GAAP EPS of $10.89–12.14. Investors should watch several headwinds: Prolia and Xgeva biosimilar erosion expected in 2025, continued net price declines for Enbrel and Repatha, high acquisition-related amortization depressing GAAP margins, and a large leverage load. Key pipeline catalysts include the UPLIZNA PDUFA date of April 3, 2025, MariTide Phase 2 Part 2 and diabetes data in H2 2025, the VESALIUS-CV outcomes readout in H2 2025, and several rocatinlimab Phase 3 readouts in H1 2025.
02—Key points
Key Highlights
- Total revenues up 19% to $33.4B for FY2024 (Q4: +11% to $9.1B); product sales up 7% ex-Horizon, indicating strong underlying organic growth
- Non-GAAP EPS rose 6% to $19.84 for FY2024 and 13% to $5.31 in Q4, while GAAP EPS fell 39% to $7.56 for the year due to acquisition amortization and equity investment losses
- Record Q4 free cash flow of $4.4B; full-year FCF of $10.4B vs. $7.4B in 2023
- Debt reduced by $4.5B in 2024 to $60.1B total; leverage approximately 4.5x EBITDA, with $12.0B in cash and investments
- 2025 guidance: total revenues of $34.3–35.7B, non-GAAP EPS of $20.00–21.20, capex of approximately $2.3B, and share repurchases up to $500M
- Strong growth from Repatha (+36% FY), TEZSPIRE (+71% FY), EVENITY (+35% FY), BLINCYTO (+41% FY), and TEPEZZA ($1.9B FY sales)
- Known headwinds for 2025 include Prolia and XGEVA biosimilar erosion, continued Enbrel net price declines, and an FDA clinical hold on the AMG 513 Phase 1 obesity study
03—Questions
Frequently Asked Questions
Why did GAAP EPS fall sharply while non-GAAP EPS grew?
GAAP EPS fell 39% to $7.56 for FY2024 because GAAP results include large Horizon acquisition-related amortization (about $7.1B in cost of sales), higher operating expenses from Horizon, and $182M of net mark-to-market losses on equity investments, primarily BeiGene. Non-GAAP EPS excludes these items, so it grew 6% to $19.84 on higher revenues.
How strong is Amgen's balance sheet and debt position?
Amgen ended 2024 with $60.1B of total GAAP debt and $12.0B of cash and investments, a debt leverage ratio of about 4.5x EBITDA. The company reduced principal debt by $4.5B during 2024 and generated $10.4B of free cash flow, providing capacity for debt repayment alongside a dividend of $2.25 per quarter (up 6% year-over-year).
What are the main growth drivers and risks for 2025?
Growth drivers include Repatha, TEZSPIRE, EVENITY, BLINCYTO, TAVNEOS, and IMDELLTRA. Risks include Prolia and XGEVA biosimilar erosion, lower Enbrel and Repatha net prices, the Horizon integration, and pipeline setbacks such as the fipaxalparant, ordesekimab, and AMG 513 programs. Q1 is typically seasonally weaker for Otezla and Enbrel due to insurance and co-pay resets.
What upcoming catalysts should investors monitor?
Key near-term catalysts include the UPLIZNA PDUFA action date of April 3, 2025 (IgG4-RD), the DeLLphi-304 Phase 3 readout for IMDELLTRA and rocatinlimab Phase 3 readouts (SHUTTLE and IGNITE) in H1 2025, and the FORTITUDE-101 bemarituzumab readout in H1 2025. Later in 2025, the VESALIUS-CV Repatha outcomes data and MariTide Phase 2 Part 2 data are expected in H2 2025.
04—Continue